Willkie Farr & Gallagher and Paul Weiss Rifkind Wharton & Garrison have taken lead roles on the $2.6bn (£1.6bn) acquisition of US drugmaker Sepracor by Japan's Dainippon Sumitomo Pharma (DSP). The all-cash purchase price represents a premium of nearly $5 (£3) per share above Sepracor's closing price on 1 September. Sepracor's board has unanimously approved the deal, under which the company will continue operating as a wholly-owned subsidiary of DSP.
September 04, 2009 at 06:04 AM
1 minute read
The original version of this story was published on Legalweek
Willkie Farr & Gallagher and Paul Weiss Rifkind Wharton & Garrison have taken lead roles on the $2.6bn (£1.6bn) acquisition of US drugmaker Sepracor by Japan’s Dainippon Sumitomo Pharma (DSP).
The all-cash purchase price represents a premium of nearly $5 (£3) per share above Sepracor’s closing price on 1 September. Sepracor’s board has unanimously approved the deal, under which the company will continue operating as a wholly-owned subsidiary of DSP.
Presented by BigVoodoo
Celebrate outstanding achievement in law firms, chambers, in-house legal departments and alternative business structures.
The African Legal Awards recognise exceptional achievement within Africa s legal community during a period of rapid change.
The premier educational and networking event for employee benefits brokers and agents.
Truly exceptional Bergen County New Jersey Law Firm is growing and seeks strong plaintiff's personal injury Attorney with 5-7 years plaintif...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
